COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Analysis of Antihypertensive Treatment Efficacy (ATACA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00767247
Recruitment Status : Terminated
First Posted : October 7, 2008
Last Update Posted : December 3, 2010
Information provided by:

Brief Summary:
Analysis of antihypertensive treatment efficacy.

Condition or disease
Arterial Hypertension

Layout table for study information
Study Type : Observational
Estimated Enrollment : 2000 participants
Observational Model: Case Control
Time Perspective: Prospective
Official Title: Analysis of Antihypertensive Treatment Efficacy
Study Start Date : May 2008
Actual Primary Completion Date : February 2009
Actual Study Completion Date : February 2009

Resource links provided by the National Library of Medicine

Male or female with arterial hypertension

Primary Outcome Measures :
  1. Analysis of antihypertensive treatment efficacy. [ Time Frame: measurement BP: 3 visits for 3 month ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
outpatient clinics

Inclusion Criteria:

  • arterial hypertension
  • intake of Atacand before study enrollment

Exclusion Criteria:

  • hypersensitivity to candesartan or any other ingredient of Atacand
  • liver function impairment and/or cholestasis
  • severe renal insufficiency (serum creatinine > 265 µmol/L)
  • Pregnant and lactating women

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00767247

Layout table for location information
Russian Federation
Research Site
Arhangelsk, Russian Federation
Research Site
Bryansk, Russian Federation
Research Site
Domodedovo, Russian Federation
Research Site
Dzerzhinsk, Russian Federation
Research Site
Ekaterinburg, Russian Federation
Research Site
Essentuki, Russian Federation
Research Site
Georgievsk, Russian Federation
Research Site
Irkutsk, Russian Federation
Research Site
Kazan, Russian Federation
Research Site
Samara, Russian Federation
Research Site
Severodvinsk, Russian Federation
Research Site
Vidnoe, Russian Federation
Research Site
Volgograd, Russian Federation
Sponsors and Collaborators
Layout table for investigator information
Principal Investigator: Dmitry Zateyshchikov, MD, Prof Federal State Institution of Russian President's General Management Department

Layout table for additonal information
Responsible Party: Andrey Strugovshchikov, Medical Director, Astra Zeneca, Russia Identifier: NCT00767247    
Other Study ID Numbers: NIS-CRU-ATA-2008/1
First Posted: October 7, 2008    Key Record Dates
Last Update Posted: December 3, 2010
Last Verified: December 2010
Keywords provided by AstraZeneca:
Arterial Hypertension
Additional relevant MeSH terms:
Layout table for MeSH terms
Vascular Diseases
Cardiovascular Diseases
Antihypertensive Agents